Norwegian energy giant Equinor is selling its onshore shale assets in Argentina's Vaca Muerta formation to local operator Vista Energy, marking a strategic pivot as it doubles down on offshore exploration and core international markets.
Despite a steep decline from its highs, UiPath's pivot towards agentic AI and a path to sustained profitability is drawing investor scrutiny. We examine its valuation, competitive moat, and growth runway in a crowded field.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
Despite a 35% monthly plunge, Hedera's HBAR shows signs of underlying buyer interest through key technical divergences. However, a critical shift in exchange flows threatens to delay any near-term price rebound, leaving the token at a pivotal juncture.
The rapid adoption of OpenClaw, an open-source autonomous AI agent platform, is moving beyond social media buzz to directly execute transactions on blockchain networks, prompting both excitement about efficiency and deep concerns over market stability and accountability.
A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.
Singapore will establish its National Space Agency on April 1st, aiming to leverage its technological prowess to secure a strategic position in the rapidly expanding global space economy, as global investments continue to soar.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
Thousands demonstrated in Milan against the planned deployment of U.S. Immigration and Customs Enforcement (ICE) agents for the 2026 Winter Games, citing human rights concerns and viewing their presence as a symbol of democratic erosion in the United States.
Generac Holdings' shares have surged 19% in a month, reigniting the debate over its valuation. While recent momentum is strong, a five-year decline of 38% underscores the challenges. Analysts see a potential upside, but risks from the residential solar slowdown and data center demand volatility loom.
Argentina has reportedly purchased $808 million in Special Drawing Rights from the U.S. Treasury to cover an upcoming interest payment to the International Monetary Fund, highlighting the nation's ongoing financial pressures.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
Google's parent company unveils an AI-powered tool for generating interactive 3D worlds, signaling a strategic push into the core technology of game development and virtual experiences, with potential ripple effects across content creation and cloud infrastructure.
Invesco Mortgage Capital (IVR) posted robust fourth-quarter results, buoyed by a calmer interest rate environment and outperformance in agency mortgage-backed securities. Executives detailed strategic portfolio positioning amid spread tightening and signaled cautious optimism for the year ahead.
New market data reveals a stark generational divide in American drinking habits, with Gen Z contributing a mere 4% to total alcohol sales last year. The findings challenge long-held industry assumptions and highlight the enduring spending power of older consumers amid a broader shift toward premiumization and alternative beverages.
The Trump administration has escalated pressure on Cuba by declaring a national emergency and threatening punitive tariffs on countries supplying it with oil, while simultaneously finalizing a reciprocal trade agreement with Guatemala aimed at bolstering Western Hemisphere supply chains.
The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
Tunisian President Kais Saied has prolonged the nation's state of emergency for an additional 11 months, maintaining exceptional powers first enacted in 2015 following a deadly attack on presidential guards.
